Lumos Diagnostics Holdings Ltd
ASX:LDX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.028
0.105
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Lumos Diagnostics Holdings Ltd
Cash & Cash Equivalents
Lumos Diagnostics Holdings Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lumos Diagnostics Holdings Ltd
ASX:LDX
|
Cash & Cash Equivalents
$6.5m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Nanosonics Ltd
ASX:NAN
|
Cash & Cash Equivalents
AU$23.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
|
Polynovo Ltd
ASX:PNV
|
Cash & Cash Equivalents
AU$45.9m
|
CAGR 3-Years
81%
|
CAGR 5-Years
27%
|
CAGR 10-Years
55%
|
|
|
SDI Ltd
ASX:SDI
|
Cash & Cash Equivalents
AU$6.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
Anteris Technologies Ltd
ASX:AVR
|
Cash & Cash Equivalents
AU$30.8m
|
CAGR 3-Years
94%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Ansell Ltd
ASX:ANN
|
Cash & Cash Equivalents
$185.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-5%
|
|
Lumos Diagnostics Holdings Ltd
Glance View
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.
See Also
What is Lumos Diagnostics Holdings Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
6.5m
USD
Based on the financial report for Jun 30, 2024, Lumos Diagnostics Holdings Ltd's Cash & Cash Equivalents amounts to 6.5m USD.
What is Lumos Diagnostics Holdings Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
17%
Over the last year, the Cash & Cash Equivalents growth was 115%. The average annual Cash & Cash Equivalents growth rates for Lumos Diagnostics Holdings Ltd have been -48% over the past three years , 17% over the past five years .
You don't have any saved screeners yet